Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[2]Alapryl in Spain,[3] and Pacinone in Portugal.[4]
Medical uses
Halazepam was used for the treatment of anxiety.[2]
Adverse effects
Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[2]
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published on June 15, 1998 as follows:[5]
Onset of action
Intermediate to slow
Plasma half life
14 hr for parent drug and 30-100 hr for its metabolite
Peak plasma levels
1-3 hr for parent drug and 3-6 hf for its metabolite
Metabolism
Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[2]
^"Alapryl". Drugs.com. Retrieved December 11, 2014.
^"Pacinone". Drugs.com. Retrieved December 11, 2014.
^Sellers EM (1998). "Antianxiety agents: benzodiazepine derivatives". In Quitkin FM, et al. (eds.). Current Psychotherapeutic Drugs (2nd ed.). Washington: American Psychiatric Press. p. 166. ISBN978-0-88048-994-2.
